BIOMAT Database Logo BIOMAT Database Logo

Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. 1988

E M Lemmel, and D Brackertz, and M Franke, and W Gaus, and P W Hartl, and K Machalke, and H Mielke, and H J Obert, and H H Peter, and J Sieper
Staatliches Rheumakrankenhaus, Baden-Baden, Federal Republic of Germany.

In a multicenter placebo-controlled double-blind randomized clinical study, 91 patients with rheumatoid arthritis were given 28 days' treatment with recombinant interferon-gamma (50 micrograms daily for 20 days, then 50 micrograms each second day up to day 28, given by subcutaneous injection). The aim of the study was to provide a methodologically clear demonstration of the efficacy of treatment with interferon-gamma, using criteria that could be handled by statistical tests. Evaluatable documentation was available for 79 patients, of whom 40 were treated with the active compound. The principal criterion for the statistical evaluation of the therapeutic success was improvement of the Ritchie "joint pain index" or Lansbury "joint pain index" by at least 30% within 28 days. The chi-square test showed superiority of the interferon arm over the placebo arm with an error probability of alpha less than 1%. In addition, efficacy of interferon-gamma was demonstrated in respect of practically all parameters investigated. The frequency of side-effects, including febrile reactions, was the same for the active compound and the placebo. During interferon treatment the daily maximum body temperature was raised by 0.3 degrees C on average, but was below 37.2 degrees C at all times.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias
D005767 Gastrointestinal Diseases Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Cholera Infantum,Gastrointestinal Disorders,Functional Gastrointestinal Disorders,Gastrointestinal Disorders, Functional,Disease, Gastrointestinal,Diseases, Gastrointestinal,Functional Gastrointestinal Disorder,Gastrointestinal Disease,Gastrointestinal Disorder,Gastrointestinal Disorder, Functional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

E M Lemmel, and D Brackertz, and M Franke, and W Gaus, and P W Hartl, and K Machalke, and H Mielke, and H J Obert, and H H Peter, and J Sieper
Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis. German Lymphokine Study Group.
January 1992, Rheumatology international,
E M Lemmel, and D Brackertz, and M Franke, and W Gaus, and P W Hartl, and K Machalke, and H Mielke, and H J Obert, and H H Peter, and J Sieper
Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study.
September 1992, Annals of the rheumatic diseases,
E M Lemmel, and D Brackertz, and M Franke, and W Gaus, and P W Hartl, and K Machalke, and H Mielke, and H J Obert, and H H Peter, and J Sieper
Interferon gamma in rheumatoid arthritis--a double blind study comparing human recombinant interferon gamma with placebo.
April 1988, The Journal of rheumatology,
E M Lemmel, and D Brackertz, and M Franke, and W Gaus, and P W Hartl, and K Machalke, and H Mielke, and H J Obert, and H H Peter, and J Sieper
A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis.
January 1997, Arthritis and rheumatism,
E M Lemmel, and D Brackertz, and M Franke, and W Gaus, and P W Hartl, and K Machalke, and H Mielke, and H J Obert, and H H Peter, and J Sieper
Treatment of rheumatoid arthritis with ornidazole: a randomized, double-blind, placebo-controlled study.
October 2006, Rheumatology international,
E M Lemmel, and D Brackertz, and M Franke, and W Gaus, and P W Hartl, and K Machalke, and H Mielke, and H J Obert, and H H Peter, and J Sieper
Treatment of rheumatoid arthritis with ornidazole. A randomized, double-blind, placebo-controlled study.
May 2006, Rheumatology (Oxford, England),
E M Lemmel, and D Brackertz, and M Franke, and W Gaus, and P W Hartl, and K Machalke, and H Mielke, and H J Obert, and H H Peter, and J Sieper
Multicenter double-blind trial of interferon-gamma versus placebo in the treatment of rheumatoid arthritis.
December 1991, Arthritis and rheumatism,
E M Lemmel, and D Brackertz, and M Franke, and W Gaus, and P W Hartl, and K Machalke, and H Mielke, and H J Obert, and H H Peter, and J Sieper
[A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis].
September 2010, Zhonghua nei ke za zhi,
E M Lemmel, and D Brackertz, and M Franke, and W Gaus, and P W Hartl, and K Machalke, and H Mielke, and H J Obert, and H H Peter, and J Sieper
Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis.
August 1989, Arthritis and rheumatism,
E M Lemmel, and D Brackertz, and M Franke, and W Gaus, and P W Hartl, and K Machalke, and H Mielke, and H J Obert, and H H Peter, and J Sieper
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
June 2017, Arthritis & rheumatology (Hoboken, N.J.),
Copied contents to your clipboard!